Free Trial

Keros Therapeutics (KROS) Stock Forecast & Price Target

$49.57
-1.25 (-2.46%)
(As of 07/24/2024 ET)

Keros Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 8 Wall Street analysts who have issued ratings for Keros Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 8 have given a buy rating for KROS.

Consensus Price Target

$88.29
78.10% Upside
High Forecast$105.00
Average Forecast$88.29
Low Forecast$60.00

According to the 8 analysts' twelve-month price targets for Keros Therapeutics, the average price target is $88.29. The highest price target for KROS is $105.00, while the lowest price target for KROS is $60.00. The average price target represents a forecasted upside of 78.10% from the current price of $49.57.

TypeCurrent Forecast
7/26/23 to 7/25/24
1 Month Ago
6/26/23 to 6/25/24
3 Months Ago
4/27/23 to 4/26/24
1 Year Ago
7/26/22 to 7/26/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$88.29$88.29$86.00$96.00
Forecasted Upside78.10% Upside77.15% Upside49.19% Upside97.60% Upside
Get Keros Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter.

KROS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KROS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Keros Therapeutics Stock vs. The Competition

TypeKeros TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside78.10% Upside3,254.43% Upside10.61% Upside
News Sentiment RatingPositive News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/25/2024Oppenheimer
3 of 5 stars
 Initiated CoverageOutperform$102.00+119.45%
6/18/2024Truist Financial
1 of 5 stars
 Reiterated RatingBuy ➝ Buy$100.00 ➝ $100.00+122.22%
6/18/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$100.00 ➝ $100.00+124.32%
3/27/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$105.00+59.60%
2/29/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$86.00+25.51%
2/21/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Phipps
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
12/8/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$60.00+68.97%
7/26/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$65.00+51.27%
2/14/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
2/14/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
12/13/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$95.00 ➝ $105.00+121.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:54 AM ET.

KROS Forecast - Frequently Asked Questions

What is Keros Therapeutics' forecast for 2024?

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Keros Therapeutics is $88.29, with a high forecast of $105.00 and a low forecast of $60.00.

Should I buy or sell Keros Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KROS shares.

Does Keros Therapeutics's stock price have much upside?

According to analysts, Keros Therapeutics's stock has a predicted upside of 77.15% based on their 12-month stock forecasts.

What analysts cover Keros Therapeutics?

Keros Therapeutics has been rated by research analysts at HC Wainwright, Oppenheimer, and Truist Financial in the past 90 days.

Do Wall Street analysts like Keros Therapeutics more than its competitors?

Analysts like Keros Therapeutics more than other "medical" companies. The consensus rating for Keros Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how KROS compares to other companies.


This page (NASDAQ:KROS) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners